

Sheet 1 of 5

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-020001/1088	Application No. 10/684,229
		Applicant Lin Zhi et al.	
		Filing Date October 10, 2003	Group Art Unit 1625

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
CA	AA	20030216388	11/20/03	Zhang et al.	514	230.5	03/12/03
CA	AB	20030220388	11/27/03	Fensome et al.	514	414	06/06/03
CA	AC	20030225109	12/04/03	Fensome et al.	514	256	04/22/03
CA	AD	2004/0147530	10/10/03	Zhi et al.	514	256	10/10/03
CA	AE	20040152717	08/05/04	Zhi et al.	514	285	10/10/03
CA	AF	20040186101	09/23/04	Zhang et al.	514	230.5	01/29/04
CA	AG	5,506,102	04/09/96	McDonnell et al.	435	6	10/28/93
CA	AH	5,688,808	11/18/97	Jones et al.	514	285	06/05/95
CA	AI	5,688,810	11/18/97	Jones et al.	514	311	06/05/95
CA	AJ	5,696,130	12/09/97	Jones et al.	514	291	06/05/95
CA	AK	5,696,133	12/09/97	Jones et al.	514	314	06/05/95
CA	AL	5,808,139	09/15/98	Pathirana et al.	560	138	09/08/94
CA	AM	5,994,544	11/30/99	Jones et al.	546	62	10/08/97
CA	AN	6,001,846	07/25/00	Bender et al.	514	285	02/17/98
CA	AO	6,093,821	07/25/00	Jones et al.	544	333	10/08/97
CA	AP	6,093,825	07/25/00	Jones et al.	546	62	05/27/98
CA	AQ	6,093,826	07/25/00	Edwards et al.	546	62	06/08/98
CA	AR	6,121,450	09/19/00	Jones et al.	546	81	10/08/97
CA	AS	6,172,241	01/09/01	Edwards et al.	549	280	10/15/99
CA	AT	6,268,497	07/31/01	Edwards et al.	546	62	04/12/00
CA	AU	6,306,851	10/23/01	Santilli et al.	514	230.5	04/19/00
CA	AV	6,319,912	10/20/01	Grubb et al.	514	171	04/19/00
CA	AW	6,329,416	12/11/01	Grubb et al.	514	415	04/19/00
CA	AX	6,339,098	01/15/02	Collins et al.	514	373	04/19/00
CA	AY	6,355,648	03/12/02	Fensome et al.	514	275	04/19/00
CA	AZ	6,358,947	03/19/02	Zhi et al.	514	229.5	04/19/00
CA	BA	6,358,948	03/19/02	Zhang et al.	514	230.5	04/19/00

Examiner Signature <i>ALIAKH</i>	Date Considered <i>12/14/05</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 18202-020001/1088		Application No. 10/684,229	
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))				Applicant Lin Zhi et al.			
				Filing Date October 10, 2003		Group Art Unit 1625	
U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
CA	BB	6,369,056	04/09/02	Zhang et al.	514	230.5	04/19/00
CA	BC	6,380,178	04/30/02	Grubb et al.	514	171	04/19/00
CA	BD	6,380,207	04/30/02	Coghlan et al.	514	285	02/13/98
CA	BE	6,380,235	04/30/02	Zhang et al.	514	395	04/19/00
CA	BF	6,391,907	05/21/02	Fensome et al.	514	409	04/19/00
CA	BG	6,399,593	06/04/02	Grubb et al.	514	171	04/19/00
CA	BH	6,407,101	06/18/02	Collins et al.	514	230.5	04/19/00
CA	BI	6,417,214	07/09/02	Ulrich et al.	514	378	04/19/00
CA	BJ	6,436,929	08/20/02	Zhang et al.	514	230.5	04/19/00
CA	BK	6,441,019	08/27/02	Santilli et al.	514	409	07/17/01
CA	BL	6,444,668	09/03/02	Grubb et al.	514	230.5	04/19/00
CA	BM	6,448,405	09/10/02	Jones et al.	546	62	10/08/97
CA	BN	6,462,032	10/08/02	Grubb et al.	514	171	04/19/00
CA	BO	6,498,154	12/24/02	Grubb et al.	514	171	04/19/00
CA	BP	6,503,939	01/07/03	Grubb et al.	514	415	10/15/01
CA	BQ	6,506,766	01/14/03	Coghlan et al.	514	285	07/05/00
CA	BR	6,509,334	01/21/03	Zhang et al.	514	230.5	04/19/00
CA	BS	6,521,657	02/18/03	Fensome et al.	514	414	10/30/01
CA	BT	6,544,970	04/08/03	Grubb et al.	514	171	05/22/02
CA	BU	6,566,358	05/20/03	Zhang et al.	514	230.5	09/06/01
CA	BV	6,566,372	05/20/03	Zhi et al.	514	312	08/24/00
CA	BW	6,583,145	06/24/03	Fensome et al.	514	256	09/24/02
CA	BX	6,608,068	08/19/03	Fensome et al.	514	256	12/11/01
CA	BY	6,693,103	02/17/04	Zhang et al.	514	256	12/17/01
CA	BZ	6,696,459	02/24/04	Jones et al.	514	285	10/14/97
CA	CA	6,713,478	03/30/04	Zhang et al.	514	230.5	03/12/03
CA	CB	6,759,408	07/06/04	Grubb et al.	514	230.5	05/09/02
Examiner Signature <i>AWLAKH</i>				Date Considered <i>12/14/05</i>			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-020001/1088	Application No. 10/684,229
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Lin Zhi et al.	
		Filing Date October 10, 2003	Group Art Unit 1625

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
CA	CC	6,794,373	09/21/04	Grubb et al.	514	171	03/01/02
CA	CD	6,835,744	12/28/04	Ullrich et al.	514	409	04/24/02
CA	CE	6,841,568	01/11/05	Fensome et al.	514	415	04/22/03

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
CA	CF	0066103	11/09/00	PCT				
CA	CG	0066163	11/09/00	PCT				
CA	CH	0066164	11/09/00	PCT				
CA	CI	0066165	11/09/00	PCT				
CA	CJ	0066166	11/09/00	PCT				
CA	CK	0066167	11/09/00	PCT				
CA	CL	0066168	11/09/00	PCT				
CA	CM	0066225	11/09/00	PCT				
CA	CN	0066554	11/09/00	PCT				
CA	CO	0066555	11/09/00	PCT				
CA	CP	0066556	11/09/00	PCT				
CA	CQ	0066560	11/09/00	PCT				
CA	CR	0066564	11/09/00	PCT				
CA	CS	0066570	11/09/00	PCT				
CA	CT	0066571	11/09/00	PCT				
CA	CU	0066574	11/09/00	PCT				
CA	CV	0066581	11/09/00	PCT				
CA	CW	0066590	11/09/00	PCT				
CA	CX	0066591	11/09/00	PCT				
CA	CY	0066592	11/09/00	PCT				
CA	CZ	0116108	03/08/01	PCT				

Examiner Signature <i>ALSLAKH</i>	Date Considered <i>12/14/05</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-020001/1088	Application No. 10/684,229
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))		Applicant Lin Zhi et al.	
		Filing Date October 10, 2003	Group Art Unit 1625

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
CA	DA	2004033459	04/22/04	PCT				
CA	DB	2004033460	04/22/04	PCT				
CA	DC	2004033461	04/22/04	PCT				
CA	DD	9619458	06/27/96	PCT				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
CA	DE	Clemm et al., "Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor," Journal of Steroid Biochemistry and Molecular Biology 53(1-6):487-495. (1995)
CA	DF	Crombie et al., "Anti-progesterone effects on maternal recognition and behaviour imprinted during first pregnancy in mice," Journal of Endocrinology 147(2):331-337. (1995)
CA	DG	Edwards et al., "5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as potent, orally active, nonsteroidal progesterone receptor agonists: the effect of D-ring substituents," Journal of Medicinal Chemistry. 41(3):303-310 (1998)
CA	DH	Edwards et al., "Preparation, resolution, and biological evaluation of 5-aryl-1, 2-dihydro-5H-chromeno[3,4-f]quinolines: potent, orally active, nonsteroidal progesterone receptor agonists," Journal of Medicinal Chemistry 41(15):2779-2785 (1998)
CA	DI	Hamann et al., "Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines," Bioorganic & Medicinal Chemistry Letters 8(19):2731-2736 (1998)
CA	DJ	Mais et al., "Specific interactions of progestins and anti-progestins with progesterone antibodies, plasma binding proteins and the human recombinant receptor," Journal of Steroid Biochemistry and Molecular Biology 54(1-2):63-69. (1995)
CA	DK	McDonnell, D. P. and M.E. Goldman, "RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism," The Journal of Biological Chemistry 269(16):11945-11949. (1994)
CA	DL	McDonnell et al., "Definition of the cellular mechanisms which distinguish between hormone and antihormone activated steroid receptors," Seminars in Cancer Biology, 5(5):327-336 (1994)
CA	DM	McDonnell et al., "The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity," Journal of Steroid Biochemistry and Molecular Biology 48(5-6):425-432. (1994)
CA	DN	Miner, J. N. and C.M. Tyree, "Drug discovery and the intracellular receptor family," Vitamins and Hormones. 62:253-280. (2001)
CA	DO	Parandoosh et al., "Progesterone and oestrogen receptors in the decidualized mouse uterus and effects of different types of anti-progesterone treatment," Journal of Reproduction and Fertility 105(2):215-220. (1995)

Examiner Signature ALLAKH	Date Considered 12/14/25
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-020001/1088	Application No. 10/684,229
List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b))			Applicant Lin Zhi et al.	
			Filing Date October 10, 2003	Group Art Unit 1625
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
CA	DP	Rosen et al., "Intracellular receptors and signal transducers and activators of transcription superfamilies - novel targets for small-molecule drug discovery," Journal of Medicinal Chemistry 38(25):4855-4874 (1995)		
CA	DQ	Santiso-Mere, D. and D.P. McDonnell, "Applied nuclear receptor research in the drug discovery process," Chimica Oggi. 12(5-6):29-36. (1994)		
LA	DR	Taylor et al., "Activity of progesterone and anti-progestins in a rat mammary primary cell culture system," Journal of Steroid Biochemistry and Molecular Biology 58(1):117-121 (1996)		
CA	DS	Vegeto et al., "Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function," Molecular Endocrinology. 7(10):1244-1255. (1993)		
LA	DT	Wagner et al., "The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: Implications for the development of dissociated antiprogestins," Endocrinology 140(3):1449-1458 (1999)		
CA	DU	Wen et al., "The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells," Molecular and Cellular Biology 14(12):8356-8364 (1994)		
LA	DV	Zhang et al., "6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: A Novel Class of Potent, Selective, and Orally Active Nonsteroidal Progesterone Receptor Antagonists," Journal of Medicinal Chemistry 45(20):4379-4382 (2002)		
CA	DW	Zhang et al., "Synthesis and progesterone receptor antagonist activities of 6-aryl benzimidazolones and benzothiazolones," Bioorganic & Medicinal Chemistry Letters 11(20):2747-2750 (2001)		
LA	DX	Zhi et al., "Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore," Bioorganic & Medicinal Chemistry Letters. 13(12):2075-2078. (2003)		
CA	DY	Zhi, et al. "Synthesis and Biological Activity of 5-Methylidene 1,2-Dihydrochromeno[3,4-f]quinoline Derivatives as Progesterone Receptor Modulators" Bioorganic & Medicinal Chemistry Letters 13:2071-2074 (2003).		
CA	DZ	Zhi et al., "5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists: effect of A-ring modification," Journal of Medicinal Chemistry. 42(8):1466-1472 (1999)		
CA	EA	Zhi et al., "5-Benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as Selective Progesterone Receptor Modulators," Journal of Medicinal Chemistry 46(19):4104-4112 (2003)		
CA	EB	Zhi et al., "Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines," Bioorganic & Medicinal Chemistry Letters. 10(5):415-418 (2000)		

Examiner Signature AULAKH	Date Considered 12/14/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	